-
Mashup Score: 0Post-Transplantation Cyclophosphamide, Tacrolimus, Mycophenolate and Mofetil vs Standard Prophylaxis for Patients With GVHD - 7 month(s) ago
Javier Bolaños Meade, MD, presents insights from a phase 3 trial on post-transplantation cyclophosphamide, tacrolimus, mycophenolate and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HLA-Haploidentical BMT With PTCy Improves Survival in SAA | ASH Clinical News | American Society of Hematology - 8 month(s) ago
Brandon May is a medical journalist based in Detroit. Upfront therapy comprising human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with post-transplantation cyclophosphamide (PTCy) was associated with an overall survival (OS) of greater than 90% at up to three years in pediatric and adult patients with severe aplastic anemia (SAA), with minimal graf t-versus-host-disease (GVHD), according to study findings published in Blood. The study also demonstrated that the use of
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD - 10 month(s) ago
TO THE EDITOR:
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update - 11 month(s) ago
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods Using EULAR standardised operating procedures, the EULAR task force undertook a…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#EULAR recommendations for management of ANCA-associated vasculitis eosinophilic granulomatosis polyangiitis eGPA ➡️ Therapy for severe AAV is #cyclophosphamide or #rituximab plus glucocorticoid 👉🏼https://t.co/MVrql0au27 Via @ARD_BMJ @eular_org Via Prof Raashid Luqmani #BSR23 https://t.co/Xz80IYGTWM
-
-
Mashup Score: 1EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update - 11 month(s) ago
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods Using EULAR standardised operating procedures, the EULAR task force undertook a…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 12Refractory Anti-NMDA Receptor Encephalitis in Early Pregnancy - 2 year(s) ago
Background and Objectives Anti-N-methyl d-aspartate receptor (NMDAR) encephalitis classically affects women of childbearing age, producing a disproportionate number of pregnant women with anti-NMDAR encephalitis. The typical presentation includes progressive neuropsychiatric symptoms, seizures, and alterations in consciousness, all of which present potential risks to the fetus. First-line and…
Categories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A phase 1b trial of ALRN-6924 in patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel has treated its first patients.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Here, Javier Bolaños Meade, MD, shares insights from a phase 3 trial on post-transplantation #cyclophosphamide, #tacrolimus, #mycophenolate, and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease #GVHD. https://t.co/EAxmL4VL87 @HopkinsMedicine https://t.co/8y1rzc2uWK